Please assess the completion status of the following clinical trial:

Trial Title: Argon Plasma Coagulation for Barrett's Esophagus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* consecutive adult patients with low-grade dysplasia in flat Barrett's mucosa referred for endoscopic treatment,~* signed an informed consent to participate in the study.~Exclusion Criteria:~* high-grade dysplasia or adenocarcinoma,~* visible lesions (nodules, ulcerations) in Barrett's mucosa,~* serious comorbidities and short life expectancy,~* coagulopathy,~* pregnancy or lactation,~* psychiatric disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APC 90W / PPI 120mg (Type: EXPERIMENTAL): treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)
- APC 90W / PPI 40mg (Type: ACTIVE_COMPARATOR): treatment with high-power argon plasma coagulation (90 Watt) followed by acid suppression with standard dose oral omeprazole (40 mg q.d)
- APC 60 W/ PPI 120mg (Type: ACTIVE_COMPARATOR): treatment with standard-power argon plasma coagulation (60 Watt) followed by acid suppression with high-dose oral omeprazole (40 mg t.i.d)

Based on this trial design, predict the completion outcome and termination type (if applicable).